Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.

[1]  A. Winstock,et al.  Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment. , 2008, Drug and alcohol review.

[2]  A. Winstock,et al.  Knowledge about buprenorphine and methadone among those receiving treatment for opioid dependence , 2008 .

[3]  N. Lee,et al.  Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified. , 2007, Drug and alcohol review.

[4]  S. Fraser,et al.  Valuing methadone takeaway doses: The contribution of service-user perspectives to policy and practice , 2007 .

[5]  Raimondo Bruno,et al.  Australian Drug Trends 2004: Findings from the Illicit Drug Reporting System (IDRS) , 2006 .

[6]  Cynthia G. McCormick,et al.  Regulatory challenges for new formulations of controlled substances in today's environment. , 2006, Drug and alcohol dependence.

[7]  J. Bell,et al.  Cycling in and out of treatment; participation in methadone treatment in NSW, 1990-2002. , 2006, Drug and alcohol dependence.

[8]  A. Muñoz,et al.  Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004. , 2005, The journal of pain : official journal of the American Pain Society.

[9]  Michael Lynskey,et al.  The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). , 2005, Drug and alcohol review.

[10]  F. Schifano,et al.  Buprenorphine mortality, seizures and prescription data in the UK, 1980–2002 , 2005, Human psychopharmacology.

[11]  A. Ritter,et al.  The relationship between take-away methadone policies and methadone diversion. , 2005, Drug and alcohol review.

[12]  C. Rabaud,et al.  Complications infectieuses et mésusage de la buprénorphine à haut dosage , 2005 .

[13]  S. Lathrop,et al.  Unintentional methadone-related overdose death in New Mexico (USA) and implications for surveillance, 1998-2002. , 2005, Addiction.

[14]  N. Clark,et al.  Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? , 2005, Addiction.

[15]  F. Baud,et al.  A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. , 2004, Addiction.

[16]  Lucie Richard,et al.  Illicit drug use and injection practices among drug users on methadone and buprenorphine maintenance treatment in France. , 2003, Addiction.

[17]  E. Southgate,et al.  The injection of methadone syrup in New South Wales: patterns of use and increased harm after partial banning of injecting equipment , 2003, Australian and New Zealand journal of public health.

[18]  G. Feeney,et al.  Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. , 2003, Drug and alcohol review.

[19]  R. Ali,et al.  Prevalence and correlates of intravenous methadone syrup administration in Adelaide, Australia. , 2003, Addiction.

[20]  J. Marsden,et al.  The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. , 2003, Addiction.

[21]  I. Varescon,et al.  Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. , 2003, Drug and alcohol dependence.

[22]  P. Kintz.  A new series of 13 buprenorphine-related deaths. , 2002, Clinical biochemistry.

[23]  O. Drummer,et al.  Fatal methadone toxicity: signs and circumstances, and the role of benzodiazepines , 2002, Australian and New Zealand journal of public health.

[24]  Shane Darke,et al.  The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. , 2002, Drug and alcohol review.

[25]  B. E. Cole.  Recognizing and Preventing Medication Diversion , 2001 .

[26]  P. Kintz.  Deaths involving buprenorphine: a compendium of French cases. , 2001, Forensic science international.

[27]  L. Kraus,et al.  Measuring alcohol consumption and alcohol-related problems: comparison of responses from self-administered questionnaires and telephone interviews. , 2001, Addiction.

[28]  D. Cranston,et al.  Patients in methadone maintenance treatment who inject methadone syrup: a preliminary study. , 2000, Drug and alcohol review.

[29]  M. Kreek,et al.  Lethal methadone intoxications in Geneva, Switzerland, from 1994 to 1998. , 2000, Addiction.

[30]  J. Strang,et al.  Randomized trial of supervised injectable versus oral methadone maintenance: report of feasibility and 6-month outcome. , 2000, Addiction.

[31]  J. Fountain,et al.  Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. , 2000, Addiction.

[32]  M. Lenné,et al.  Methadone injecting in Australia: a tale of two cities. , 1999, Addiction.

[33]  M. Stitzer,et al.  Controlled opioid withdrawal evaluation during 72 h dose omission in buprenorphine-maintained patients. , 1997, Drug and alcohol dependence.

[34]  W. Hall,et al.  Prevalence and correlates of the injection of methadone syrup in Sydney, Australia. , 1996, Drug and alcohol dependence.

[35]  J. Howard,et al.  "Non injectables": methadone syrup and benzodiazepine injection by methadone-maintained clients. , 1996, Drug and alcohol review.

[36]  G. Gessa,et al.  Prohibition of take-home dosages: negative consequences on methadone maintenance treatment. , 1996, Drug and alcohol dependence.

[37]  K. Preston,et al.  Acute administration of buprenorphine in humans: partial agonist and blockade effects. , 1995, The Journal of pharmacology and experimental therapeutics.

[38]  J. Vincelette,et al.  Illicit use of methadone among i.v. drug users in Montreal. , 1994, Journal of substance abuse treatment.

[39]  W. Aquilino.  INTERVIEW MODE EFFECTS IN SURVEYS OF DRUG AND ALCOHOL USE: A FIELD EXPERIMENT , 1994 .

[40]  K. Preston,et al.  Clinical pharmacology of buprenorphine: Ceiling effects at high doses , 1994, Clinical pharmacology and therapeutics.

[41]  C. Rabaud,et al.  [Infectious complications and misuse of high-dose buprenorphine]. , 2005, Presse medicale.

[42]  G. Gmel.  The effect of mode of data collection and of non-response on reported alcohol consumption: a split-sample study in Switzerland. , 2000, Addiction.

[43]  S. Sunjic,et al.  Deaths in methadone maintenance treatment in New South Wales, Australia 1990-1995. , 2000, Addiction.

[44]  J. Schmitz,et al.  Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. , 1998, American journal of public health.

[45]  J. Strang,et al.  Eating Too Little, Smoking and Drinking Too Much: Wider Lifestyle Problems Among Methadone Maintenance Patients , 1998 .